Nectar Lifesciences Ltd banner

Nectar Lifesciences Ltd
NSE:NECLIFE

Watchlist Manager
Nectar Lifesciences Ltd Logo
Nectar Lifesciences Ltd
NSE:NECLIFE
Watchlist
Price: 13.27 INR 0.76% Market Closed
Market Cap: ₹3B

Relative Value

The Relative Value of one NECLIFE stock under the Base Case scenario is hidden INR. Compared to the current market price of 13.27 INR, Nectar Lifesciences Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NECLIFE Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

NECLIFE Competitors Multiples
Nectar Lifesciences Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Nectar Lifesciences Ltd
NSE:NECLIFE
3B INR 0.4 -0.8 -1.5 -1.2
US
Eli Lilly and Co
NYSE:LLY
961.6B USD 14.8 46.6 31.4 33.4
US
Johnson & Johnson
NYSE:JNJ
588.7B USD 6.2 22 15.2 18.7
CH
Roche Holding AG
SIX:ROG
295B CHF 4.8 31.4 13.2 15.4
UK
AstraZeneca PLC
LSE:AZN
242.6B GBP 5.6 32.3 17.8 25.1
CH
Novartis AG
SIX:NOVN
248.1B CHF 5.7 22.8 14 18
US
Merck & Co Inc
NYSE:MRK
301.6B USD 4.6 16.5 10.3 12.1
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.4 9.8 11.5
US
Pfizer Inc
NYSE:PFE
155.7B USD 2.5 20 7.5 10
UK
GlaxoSmithKline PLC
LSE:GSK
92.5B GBP 2.8 16.2 8.1 11.5
P/E Multiple
Earnings Growth PEG
IN
Nectar Lifesciences Ltd
NSE:NECLIFE
Average P/E: 24.6
Negative Multiple: -0.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.6
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22
7%
3.1
CH
Roche Holding AG
SIX:ROG
31.4
29%
1.1
UK
AstraZeneca PLC
LSE:AZN
32.3
26%
1.2
CH
Novartis AG
SIX:NOVN
22.8
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.5
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
7%
1.9
US
Pfizer Inc
NYSE:PFE
20
26%
0.8
UK
GlaxoSmithKline PLC
LSE:GSK
16.2
18%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Nectar Lifesciences Ltd
NSE:NECLIFE
Average EV/EBITDA: 46
Negative Multiple: -1.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.4
18%
1.7
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
13.2
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
17.8
11%
1.6
CH
Novartis AG
SIX:NOVN
14
9%
1.6
US
Merck & Co Inc
NYSE:MRK
10.3
7%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.8
7%
1.4
US
Pfizer Inc
NYSE:PFE
7.5
-4%
N/A
UK
GlaxoSmithKline PLC
LSE:GSK
8.1
2%
4.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Nectar Lifesciences Ltd
NSE:NECLIFE
Average EV/EBIT: 99.1
Negative Multiple: -1.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.4
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.7
6%
3.1
CH
Roche Holding AG
SIX:ROG
15.4
6%
2.6
UK
AstraZeneca PLC
LSE:AZN
25.1
24%
1
CH
Novartis AG
SIX:NOVN
18
12%
1.5
US
Merck & Co Inc
NYSE:MRK
12.1
6%
2
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
8%
1.4
US
Pfizer Inc
NYSE:PFE
10
-1%
N/A
UK
GlaxoSmithKline PLC
LSE:GSK
11.5
12%
1